Rivaroxaban was extracted from Xarelto® 20 mg tablets (Bayer). A single tablet was dissolved in 1 ml Dimethyl sulfoxide, vortexed and diluted in calcium-free PBS to generate 2.6 μg/ml of the Rivaroxaban working solution. The exact active concentration was determined using a Liquid Anti-Xa assay kit (IL, Italy) based on a calibration curve generated with commercial Rivaroxaban calibrators (IL, Italy) and FXDP (IL, Italy) on an ACL-TOP 500 automated coagulometer (IL, Italy) according to manufacturer directions. Rivaroxaban was added up to a final concentration of 800 ng/ml in 200 ng/ml increments. Normal plasma pool (IL, Italy) served as a control. Coagulant activity was immediately measured using an extended PT assay.
Xarelto 20 mg tablets
Manufactured by Bayer
Sourced in Germany, Mexico
Xarelto® 20 mg tablets is a prescription medication used to treat and prevent blood clots. It is an oral anticoagulant that works by inhibiting the activity of a specific clotting factor in the body.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using xarelto 20 mg tablets
1
Rivaroxaban Quantification and Coagulant Activity
2
Rivaroxaban Dosage Evaluation in Dogs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Commercially available 20 mg rivaroxaban tablets (Xarelto 20 mg tablets; Bayer HealthCare AG, Leverkussen, Germany) were split using a pill cutter and then administered to the dogs. Single PO doses of rivaroxaban at 0.5, 1, 2, and 4 mg/kg were administered to 6 dogs with a 2‐week washout period between the different dosages. To detect residual activity and cumulative effect of rivaroxaban, 0.5 and 1 mg/kg rivaroxaban were administered to 3 randomly selected dogs every 24 hours for 3 consecutive days. The dogs were not fasted and were evaluated twice daily during the study for any adverse effects. General physical examination and signs of bleeding were evaluated.
3
Xarelto and Rivaroxaban Bioequivalence Study
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The reference and test formulations used in this study were Xarelto 20‐mg tablets (lot no. BXHZ5T1, expiration date October 2019; Bayer de México, SA de CV, Mexico) and Rivaroxaban 20‐mg tablets (lot no. 8MXA002; expiration date July 2020; Sanofi Aventis de Mexico, S.A. de CV, Mexico), respectively.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!